United States · FDA National Drug Code directory
PERTZYE
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 59767-024_2ae80639-0555-49c6-bae7-00f43983e614
- Product NDC
- 59767-024
- Form
- CAPSULE, DELAYED RELEASE
- Composition / generic term
- pancrelipase
- Labeler
- Digestive Care, Inc.
- Marketing category
- BLA
- Marketing start / end (source format)
- 20170713
- Source listing expiry
- 20261231
Source-listed ingredients
- PANCRELIPASE LIPASE — 24000 [USP'U]/1
- PANCRELIPASE AMYLASE — 90750 [USP'U]/1
- PANCRELIPASE PROTEASE — 86250 [USP'U]/1
These values do not establish equivalence or a dose recommendation.
Packages
- 20 CAPSULE, DELAYED RELEASE in 1 BOTTLE (59767-024-00) · 59767-024-00
- 80 CAPSULE, DELAYED RELEASE in 1 BOTTLE (59767-024-01) · 59767-024-01
- 200 CAPSULE, DELAYED RELEASE in 1 BOTTLE (59767-024-02) · 59767-024-02
- 80 CAPSULE, DELAYED RELEASE in 1 BOTTLE (59767-024-99) · 59767-024-99
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →